Ciclesonide
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Perennial Allergic Rhinitis
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Trial Timeline
Jan 1, 2005 โ Aug 1, 2005
NCT ID
NCT00163488About Ciclesonide
Ciclesonide is a phase 3 stage product being developed by AstraZeneca for Perennial Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00163488. Target conditions include Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01455194 | Phase 3 | Completed |
| NCT00608218 | Pre-clinical | Completed |
| NCT00305461 | Phase 3 | Completed |
| NCT00261287 | Phase 3 | Completed |
| NCT00163371 | Phase 3 | Completed |
| NCT00163436 | Phase 3 | Completed |
| NCT00163488 | Phase 3 | Completed |
| NCT00163423 | Phase 3 | Completed |
| NCT00163319 | Phase 3 | Completed |
| NCT00163462 | Phase 3 | Completed |
| NCT00163514 | Phase 3 | Completed |
| NCT00163384 | Phase 3 | Completed |
| NCT00163397 | Phase 3 | Completed |
| NCT00163501 | Phase 3 | Completed |
| NCT00163345 | Phase 3 | Completed |
| NCT00163358 | Phase 3 | Completed |
| NCT00163410 | Phase 3 | Completed |
| NCT00163332 | Phase 3 | Completed |
| NCT00546520 | Phase 3 | Completed |
Competing Products
20 competing products in Perennial Allergic Rhinitis